As the cost of health care continues to rise, many employers have instituted population health management programs designed to reduce and manage health risks of their employees. It is an important part of preventive medicine, chronic condition management, and population health.
As the cost of health care continues to rise, many employers have instituted population health management programs designed to reduce and manage health risks of their employees. It is an important part of preventive medicine, chronic condition management, and population health. 1 These programs have further expanded under the 2010 Patient Protection and Affordable Care Act provision that allows employers to offer financial incentives, up to 30% of the total cost of health coverage, to encourage employee participation. One of the key components of such a wellness program is biometric screening. 2 "Biometric screening is the measurement of physical characteristics such as height, weight, body mass index, blood pressure, blood cholesterol, blood glucose, and aerobic Upon completion of this activity you will be able to:
• describe the different methodologies for measurement of hemoglobin A 1c (HbA 1c ).
• explain the biochemical interaction of hemoglobin variants with each type of hemoglobin A 1c methodology and how this can affect results.
• recognize pitfalls in the interpretation of HbA 1c and when results that are discordant with the clinical situation should prompt further investigation.
• develop an approach to incidental findings found during HbA 1c testing.
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Wilburn et al / Role of Hemoglobin VaRiants fitness tests that can be taken at the worksite and used as part of a workplace health assessment to benchmark and evaluate changes in employee health status over time." 3 The results of the biometric screening allow employers to tailor programs centered on lifestyle, chronic condition medical management, coordination of care, and behavioral modification to improve health risk factors in their employees. 4 Hemoglobin A 1c (HbA 1c ) is frequently used in biometric screening as a biomarker for glycemic status and risk toward the development or complications of diabetes. 5 HbA 1c is formed from the posttranslational nonenzymatic addition of glucose to the N-terminal valine of the β-chain of hemoglobin (Hb) A through an Amadori rearrangement. 6 The amount of HbA that undergoes glycation is directly proportional to the concentration of blood glucose and the time the RBCs remain in circulation. 6 Several studies have established a well-defined relationship between HbA 1c and average blood glucose concentrations. 6 Hence, HbA 1c is one of the most widely used biomarkers of glycemic status and control in diabetes testing and treatment. 6 The utility of HbA 1c testing expanded in 2009, with the International Expert Committee report adding that an HbA 1c of 6.5% or more alone was sufficient for diagnosis of diabetes. 7 Currently, there are five major methods for HbA 1c measurement: borate affinity, immunoassay, enzymatic, ion-exchange high-performance liquid chromatography, and capillary electrophoresis. 8 Each of these methods displays analytical sensitivity, specificity, and imprecision that are acceptable to the National Glycohemoglobin Standardization Program (NGSP) for HbA 1c measurement. Most patients have wild-type Hb (HbA) and thus the choice of method for HbA 1c measurement will not drastically affect interpretation of their results. 9 However, for individuals with an Hb variant, the choice of testing method can result in spuriously high or low HbA 1c values. 10 The effect of Hb variants on HbA 1c measurement comes from direct interference with the testing modality, reduction of the RBC life span, or both.
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Of the four methods, immunoassay and borate affinity are unable to detect Hb variants. 12 Borate affinity shows the least interference by Hb variants in HbA 1c measurement through separation and quantitation of both glycated and nonglycated Hb species, regardless of structural differences. 13 Most immunoassays perform spectrophotometric measurement of total Hb at or near the Sorbet band of absorption (410-420 nm), produced by the characteristic π→π* electron transition that is an intrinsic property of porphyrin rings.
14 In all stable and some unstable Hb variants, the mutations in the α-or β-chain do not affect the incorporation of the porphyrin ring, 15 and therefore, the variant Hb will be included in the total Hb concentration used to calculate HbA 1c . 16 For the borate affinity and immunoassays that have antibody reactivity with glycated variants, the accuracy of the HbA 1c /glycation measurement depends on the assumption that the rate of glycation of the variant Hb is similar to that of HbA. 17 However, as research into the biochemistry of variant Hb has progressed, stark differences in glycation rates between HbA and variants have been identified. 18, 19 The glycation of Hb is a function of time and glucose concentration; therefore, changes in RBC life span will affect the HbA 1c , especially given that Hb in younger RBCs undergoes glycation at a slower rate. 20 Few studies have been conducted to determine the RBC life span of individuals who are heterozygous for a particular Hb variant, leaving concern over the validity of HbA 1c measurement in those individuals. 21 This concern is supported by the finding of Shima et al 20 that RBC life span was significantly correlated with HbA 1c measurements, and patients with diabetes who had end-stage renal disease had significantly lower HbA 1c and RBC life spans compared with their diabetic peers without end-stage renal disease but equivalent glycemic control.
Interpretation of HbA 1c studies performed by ion-exchange chromatography and capillary electrophoresis requires sound knowledge of the prevalence and type of Hb variants among one's patient population, as certain variants can comigrate with normal Hb fractions. 22, 23 This study outlines our experience with performing HbA 1c analyses in a large multiethnic population with a focus on the effect of variants on our testing method and results, as well as the challenges surrounding reporting incidental findings of Hb variants.
Materials and Methods
This study was approved by the institutional review board at Houston Methodist Hospital in accord with the ethical standards established by the institution. Over a period of 2.5 months, 16,632 individuals composed of employees and their spouses underwent biometric screening as part of the hospital's wellness program. In total, 13,913 of those individuals had the laboratory component of the biometric screening performed at our central laboratory. The wellness program includes HbA 1c measurement to assess each individual's glycemic status to identify those who would benefit from programs focused on glycemic control. At our institution, HbA 1c is measured via ion-exchange high-performance liquid chromatography on the Bio-Rad VARIANT II Turbo 2.0 (Bio-Rad, Hercules, CA) testing system on whole-blood samples collected in K 2 -EDTA tubes. Samples that had a variant Hb detected in the combined S, D, and E window or C window or had an HbF fraction more than 25% underwent variant Hb characterization and confirmation through performance of an Hb gel electrophoresis at both acidic (6.0) and alkaline (8.5) pH on the Sebia HYDRASYS 2 system (Sebia, Norcross, GA). In addition, these same samples had a CBC performed on a Sysmex XN-9000 (Sysmex, Lincolnshire, IL) automated hematology analyzer to assess the patient's RBC indices (Hb, hematocrit, RBC, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration) for possible concomitant thalassemia. Samples with variants not resolved by electrophoresis were sent to a reference laboratory (ARUP Lab, Salt Lake City, UT) for further characterization.
Results
Of the 13,913 individuals who underwent HbA 1c evaluation at our central laboratory, 524 (3.77%) had an Hb variant. The prevalence of each individual variant and concomitant thalassemia is shown in ❚Table 1❚.
The retention times in minutes of each individual Hb are shown in ❚Table 2❚.
Discussion
Prior to using the Bio-Rad VARIANT II Turbo 2.0 for HbA 1c measurement, our laboratory used the Roche TinaQuant HbA 1c Gen The package insert for the Bio-Rad VARIANT II Turbo 2.0 states that the method does not show significant interference (>6%) from the presence of HbE so long as it is less than 60% of the total Hb. 26 However, there have been conflicting reports in the literature from postmarketing studies. One group found that the Bio-Rad VARIANT II Turbo 2.0 had upward of a 10% positive bias for HbA 1c measurements at the medical decision level in individuals heterozygous for HbE. 27 The positive bias was attributed to the chromatographic separation of HbE and HbA 0 , such that HbE eluted in a variant window as a split peak of A 0 . Given that the VARIANT II Turbo 2.0 does not include the area under the curve of any peak in the variant window in the calculation of HbA 1c , the percentage of HbA would be underestimated, resulting in falsely elevated HA 1c . We also observed the same split peak in A 0 for the 18 individuals in our study who were heterozygous for HbE ❚Figure 1❚. The HA 1c results for the HbE heterozygous individuals were not cross-checked using a different assay; therefore, we cannot add to the discussion of HA 1c accuracy among this population when tested with this assay. However, the HA 1c results of our 18 HbE heterozygous individuals ranged from 5.2% to 6.2%; therefore, even if a 10% positive bias affected these results, none of our individuals were falsely diagnosed with diabetes. However, 11 (61%) of these 18 individuals had HbA 1c values of 5.7% or more and, therefore, could have been misdiagnosed as having prediabetes. In future years' biometric screening, individuals who are known or newly identified as having HbE will have their glycemic status assessed through performance of a fasting plasma glucose.
Our experience above demonstrates the benefits of HbA 1c measurement platforms that allow for identification of Hb variants. This benefit is maximized by the ordering provider or the laboratory through consultation, combining epidemiological knowledge of variant Hb with an understanding of each HbA 1c method's Hb variant detection capability and interference profile. The NGSP has supported such efforts by making a guide that displays each HbA 1c method platform's susceptibility to interference from common Hb variants. 28 This knowledge will become ever more important as our general population becomes more multiethnic and the distribution of Hb variants moves outside traditional regional boundaries.
The findings from our biometric screening program serve as a prime example of the effect of migration on a population's Hb variant distribution. In a 2008 bulletin, the World Health Organization (WHO) provided statistics on the worldwide prevalence of Hb disorders. For the WHO region of North and South America, the prevalence of significant Hb variants was 3.0%. A significant variant was defined as HbS, HbC, HbE, or HbD; β-thalassemia; and αα/--thalassemia. The total prevalence worldwide of significant variants was 5.2%. 29 A prevalence of 3.77% of individuals in our population having a significant Hb variant was higher than the measured rate of 3.0% among North and South Americans in the WHO study and may underestimate the true incidence, especially when we take into account that we did not screen all individuals for β-thalassemia using a CBC. The prevalence of significant Hb variants in our study serves as a reflection of our metropolitan area being the fourth largest in the United States, ranked eight out of 366 for ethnic diversity in a 2010 study by Brown University, and having long served as a hub of international industry and trade. 30 Having such a multiethnic participant population presented the new issue of incidental findings when our institution switched from immunoassay to chromatography, allowing the detection of Hb variants during HbA 1c testing. Most of the literature on incidental findings focuses on radiological studies, intraoperative findings, and the ever-growing field of genomics. 31, 32 In these discussions, the critical aspects center on the patients' or participants' knowledge of possible incidental findings from the test performed, their expectation that any abnormal finding would be reported to them regardless, the duty of the doctor to inform the patients or participants of the finding, and the "medical actionability" of the finding. 33 The controversy over reporting incidental findings stems from the fact that not all findings are beneficial to the patient's health. Often an incidental finding leads to undue emotional turmoil in the patient that is accompanied by repeat or expanded testing and substantially increased cost. Also, certain patients may not want to know these findings. For these reasons, some clinicians would argue that releasing incidental findings without applying clinical judgment is 34 However, with the increased focus on patient autonomy in current medical practice, many medical professional governing bodies have moved to support disclosure of incidental findings with systems designed to empower the patient in the decision of hearing the findings or how to proceed to address the issue. 35 Unlike an incidental mass found during a radiological survey, the "medical actionability" of a possible newly determined variant Hb is clear. 36 Many of the variants in heterozygous form, such as HbD, HbG, or Montgomery ❚Figure 2❚ in this study, are typically asymptomatic and of importance only in terms of family planning. Although it would be unlikely for individuals who are part of the adult workforce to still have undiagnosed HbSS, HbSC, or HbCC disease, it is not out of the realm of possibility. Providing such individuals knowledge of their disease and directing them to the appropriate health care resources prior to their presentation secondary to complications serves as a direct example of the principle of beneficence in medicine. For those who are identified as being heterozygous, the knowledge plays a role not only in family planning but also in understanding one's risk of complications when the body is subjected to extreme environmental conditions. 37 However, not all individuals may want to know if they are found to have a variant Hb incidentally. As hemoglobinopathies are heritable conditions, divulgence always carries the risk of harm by bringing to question the validity of stated family relations and emotional duress on the part of a parent who has unknowingly passed the condition on to his or her offspring. In consideration of these risks and benefits, we adopted the following system for notification of the finding of a variant Hb during our 2015 biometric screening program: all individuals found to be heterozygous for a variant Hb were notified by mail that a variant Hb (type not specified) had been detected during their HA 1c testing, and follow-up with their primary care provider was recommended. Individuals found to be homozygous or a compound heterozygote for HbS or HbC were contacted by phone by a trained member of our wellness team to discuss the findings with the patients and direct them to the appropriate health care resources if necessary.
The primary limitation in this study was that the Hb variants were not fully confirmed by genetic sequencing. A further limitation exists in the form of sample bias. Not all individuals in our health system had the laboratory component of their 2015 biometric screening performed by our central laboratory. A total of 2,719 (16% of the total participant population) individuals had their laboratory testing performed after visiting their primary care provider (PCP). Ethnic minorities are less likely to than their peers to use health care resources even when controlling for level of access. 38 By not including the group of individuals who were tested by their PCP, a bias toward a higher prevalence of Hb variants could have been made.
Conclusion
This study represents one of the largest epidemiologic investigations into the prevalence of Hb variants in a North American metropolitan, multiethnic workforce and their dependents. Of course, such an epidemiologic study was not our initial goal. These findings rose out of our institution's journey to find an HbA 1c measurement method and platform that would provide robust performance and accurate results for our employee wellness biometric screening program. Our experience with HbA 1c testing provides insight into the global migration of Hb variants, the importance of method selection in populations with Hb variants, and the ethics involved in the management of incidental finding disclosure.
The Hb variance rate of 3.77% among the participants determined from this study is an extension of the multiethnicity of not only our employees and their dependents but also our metropolitan area. The results serve as a reminder that as global migration and integration progress, the current regional and ethnic boundaries of Hb variants will continue to evolve. With this evolution, the effectiveness of applying heuristic models to determine the risk of a patient having a variant Hb will diminish. In tandem with this progression, providers and laboratories alike will need to gain deeper knowledge of their HbA 1c method's performance characteristics in patients with Hb variants. The overestimation of HbA 1c results due to HbA 0 and HbE not being fully chromatographically resolved on the Bio-Rad VARIANT II Turbo 2.0 is a prime example. Having this knowledge will allow us to provide 18 individuals with a more accurate measurement of their glycemic status. Most important, immunoassay and borate affinity methods cannot detect Hb variants and, therefore, would not be recommended for use in populations with a high prevalence of Hb variants.
Finally, when using an HbA 1c measurement method that can detect Hb variants, a policy for addressing incidental findings needs to be developed. Such a policy should balance the principle of beneficence with patient autonomy and concern for harm.
